Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.

BACKGROUND Exogenous administration of glucagon-like peptide (GLP)-1 improves glucose tolerance by stimulation of insulin secretion, inhibition of glucagon secretion, and delay of gastric emptying. It is not known which of these effects is involved in the action of endogenous GLP-1 to control blood glucose. To determine the role of endogenous GLP-1 on islet cell function and gastric emptying independent of variable glycemia, we clamped blood glucose before and during glucose ingestion with and without GLP-1 receptor blockade with exendin-[9-39] (Ex-9). METHODS There were 10 healthy subjects that participated in two experiments each, one a control and one with infusion of 750 pm/kg . min Ex-9. Subjects consumed 75 g oral glucose solution mixed with d-xylose and (13)C-glucose while their blood glucose levels were held fixed at approximately 8.9 mmol/liter. RESULTS Plasma insulin levels during hyperglycemia alone were similar in the two studies (control, 282.5 +/- 42 vs. Ex-9, 263.8 +/- 59 pmol/liter) but were reduced by approximately 30% by Ex-9 after glucose ingestion (control, 1154 +/- 203 vs. Ex-9, 835 +/- 120 pmol/liter; P < 0.05). Blocking the action of endogenous GLP-1 caused an approximate 80% increase in postprandial glucagon concentrations. The appearance of ingested d-xylose in the blood was not affected by Ex-9, suggesting that postprandial secretion of GLP-1 has only minimal effects on gastric emptying of oral glucose. CONCLUSIONS These findings indicate that GLP-1 is an incretin in healthy humans at modestly supraphysiological blood glucose levels. The primary effect of GLP-1 to regulate oral glucose tolerance is mediated by effects on islet hormones and not on gastric emptying.

[1]  Michael Camilleri,et al.  Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes , 2007, Diabetes.

[2]  J. Holst,et al.  Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects , 2007, Diabetologia.

[3]  B. Göke,et al.  Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans , 2005, Gut.

[4]  R. Wadwa,et al.  β-Cell Function, Insulin Sensitivity, and Glucose Tolerance in Obese Diabetic and Nondiabetic Adolescents and Young Adults , 2006 .

[5]  J. Holst,et al.  Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man , 1993, Digestive Diseases and Sciences.

[6]  O. Schmitz,et al.  GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[7]  M. Laville,et al.  Use of a new gas chromatograph isotope ratio mass spectrometer to trace exogenous 13C labelled glucose at a very low level of enrichment in man , 1990, Diabetologia.

[8]  D. D’Alessio,et al.  Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. , 2003, American journal of physiology. Endocrinology and metabolism.

[9]  J. Holst,et al.  Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects , 2003, Regulatory Peptides.

[10]  J. Holst,et al.  Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. , 2002, The Journal of clinical endocrinology and metabolism.

[11]  B. Brinkmann,et al.  Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[12]  J. Holst,et al.  Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.

[13]  E. Husebye,et al.  Stimulation of the small intestine by nutrients in relation to phase of the migrating motor complex. , 2000, Scandinavian journal of gastroenterology.

[14]  J. Habener,et al.  The glucagon-like peptides. , 1999, Endocrine reviews.

[15]  M. Nauck.  Is glucagon-like peptide 1 an incretin hormone? , 1999, Diabetologia.

[16]  S. Bloom,et al.  Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. , 1999, Diabetes.

[17]  S. Rössner,et al.  Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. , 1998, The American journal of clinical nutrition.

[18]  B. Göke,et al.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. , 1998, The Journal of clinical investigation.

[19]  J. Holst,et al.  Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients , 1996, Diabetes Care.

[20]  D. D’Alessio,et al.  Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. , 1996, The Journal of clinical investigation.

[21]  B. Göke,et al.  Gastric emptying and release of incretin hormones after glucose ingestion in humans. , 1996, The Journal of clinical investigation.

[22]  M. Nauck,et al.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.

[23]  S. Bardet,et al.  Inter and intra individual variability of acute insulin response during intravenous glucose tolerance tests. , 1989, Diabete & metabolisme.

[24]  R. Eaton,et al.  Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. , 1986, The Journal of clinical endocrinology and metabolism.

[25]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[26]  M. Glick,et al.  A simplified, colorimetric micromethod for xylose in serum or urine, with phloroglucinol. , 1979, Clinical chemistry.

[27]  J. Brown,et al.  Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. , 1978, The Journal of clinical investigation.